SABPA OC/LA 16th Annual Biomedical Forum
SoCal Association for Biomedical and Pharmaceutical Adv...
Welcome to the 5th Annual Biomedical Forum. This year’s program will focus on the latest innovations in medical devices and biotechnology/ pharmaceutical industries, as well as business opportunities to thrive in the new economy amid global financial challenges. The mission of this forum is to provide an attractive platform for entrepreneurs, scientists, engineers, investors, executives, and policy makers to promote life sciences, biotechnology, pharmaceutical, medical device and alliances across the biomedical industry in Southern California and Asia. The annual biomedical forum is one of the flagship events organized by SABPA OC/LA, which consistently attracted more than 200 attendees. This year, we have brought to you pioneers and renowned innovators in the field, as well as exhilarating entrepreneurs that help accelerate the development of technology into clinical practices. Furthermore, we will introduce two Special Reports from China to join the discussion on reviving the economy from global operation perspective. I hope you will enjoy the program.
Hengchu Cao, PhD
President, SABPA OC/LA
a:25:{i:0;a:3:{s:12:"time_program";s:7:"8:00 am";s:19:"description_program";s:0:"";s:7:"program";s:34:"Registration
Coffee and Breakfast";}i:1;a:3:{s:12:"time_program";s:7:"8:15 am";s:19:"description_program";s:112:"Hengchu Cao, PhD.
President, SABPA OC/LA
Matthew Jenusaitis, MBA.
President and CEO, OCTANe";s:7:"program";s:89:"Opening Remarks CA Medical Devices and the Importance of a Robust International Strategy";}i:2;a:3:{s:12:"time_program";s:9:"Session I";s:19:"description_program";s:51:"Moderator:Fred Ouyang, PhD, MBA.
Allergan, Inc";s:7:"program";s:52:"Global Trends in Biotech and Pharmaceutical Industry";}i:3;a:3:{s:12:"time_program";s:7:"8:45 am";s:19:"description_program";s:134:"Philip Schwartz, PhD.
Director, National Human Neural Stem Cell Resource, Childrens Hospital of Orange County Research Institute ";s:7:"program";s:54:"Human Neural Stem Cells for Therapy and Gene Discovery";}i:4;a:3:{s:12:"time_program";s:8:"9:15 am ";s:19:"description_program";s:59:"Ji Li, PhD.
Director, External R&D Affairs, Amgen Inc.";s:7:"program";s:28:"Partnering Approach at Amgen";}i:5;a:3:{s:12:"time_program";s:7:"9:45 am";s:19:"description_program";s:62:"William Martin, PhD.
Laboratory Director, PRL-SW, US FDA ";s:7:"program";s:168:"Adulteration in the Foods, Dietary Supplement/Herbal Products and Medical Products Industries: Domestic and Import Observations and the Quality Challenges to Industries";}i:6;a:3:{s:12:"time_program";s:8:"10:15 am";s:19:"description_program";s:0:"";s:7:"program";s:12:"Coffee Break";}i:7;a:3:{s:12:"time_program";s:10:"Session II";s:19:"description_program";s:59:"Moderator:Xiao-Yan Gong,PhD.
Medical Implant Mechanics";s:7:"program";s:37:"Innovation in Medical Device Industry";}i:8;a:3:{s:12:"time_program";s:8:"11:00 am";s:19:"description_program";s:87:"Sanjay Shrivastava, PhD.
Director, Research & Development, EV3 Neurovascular, Inc ";s:7:"program";s:104:"Materials and Design Considerations in Endovascular Treatments of Ischemic Stroke and Cerebral Aneurysms";}i:9;a:3:{s:12:"time_program";s:9:"11:30 am ";s:19:"description_program";s:90:"K. T. Rao, PhD.
Chief Scientific Officer and Vice President, Nellix Endovascular Inc.";s:7:"program";s:40:"Fillable Endovascular Aneurysm Treatment";}i:10;a:3:{s:12:"time_program";s:8:"12:00 pm";s:19:"description_program";s:0:"";s:7:"program";s:29:"Lunch and Visit Exhibit Booth";}i:11;a:3:{s:12:"time_program";s:11:"Session III";s:19:"description_program";s:43:"Moderator: Scott Lopez
Biotronik, Inc.";s:7:"program";s:27:"Global Operation Strategies";}i:12;a:3:{s:12:"time_program";s:7:"1:00 pm";s:19:"description_program";s:109:"Fidela Moreno MD, VP, Global Development Operations/ Clinical Site Management and Monitoring, Allergan Inc. ";s:7:"program";s:94:"The Globalization of Clinical Trials: Opportunities and Challenges for the Asia Pacific Region";}i:13;a:3:{s:12:"time_program";s:7:"1:20 pm";s:19:"description_program";s:50:"Sabing Lee, JD, Knobbe, Martens, Olson & Bear, LLP";s:7:"program";s:74:"Best Practices for Protecting Your Technology and IP in the U.S. and China";}i:14;a:3:{s:12:"time_program";s:7:"1:40 pm";s:19:"description_program";s:120:"Paul A. DeRidder, MD, MBA.
Venture Partner-Crystal Cove Capital, Partner-Ampleluck International Capital Group, Ltd";s:7:"program";s:39:"China Angel Investment: A New Beginning";}i:15;a:3:{s:12:"time_program";s:7:"2:00 pm";s:19:"description_program";s:120:"James Jiayuan Tong, MD, PhD.
Chief Financial Officer, Chief Business Development Officer Tianyin Pharmaceutical Co.";s:7:"program";s:55:"China BioMedical, PIPE's, M&A and other Exit Strategies";}i:16;a:3:{s:12:"time_program";s:7:"2:20 pm";s:19:"description_program";s:0:"";s:7:"program";s:5:"Break";}i:17;a:3:{s:12:"time_program";s:10:"Session IV";s:19:"description_program";s:58:"Moderator : John Shu, JD, Stradling Yocca Carlson & Rauth ";s:7:"program";s:29:"Global Economic Collaboration";}i:18;a:3:{s:12:"time_program";s:7:"2:40 pm";s:19:"description_program";s:66:"Andrew Pan, North America Representative Office of Shenzhen, China";s:7:"program";s:120:"Shenzhen-China's City of Innovation and Entrepreneurship--Update, Opportunities and Case Study in Biotechnology Industry";}i:19;a:3:{s:12:"time_program";s:7:"3:00 pm";s:19:"description_program";s:95:"Steve Jia, PhD, Co-founder and President , PacificBio Inc. & CTO, Shenyang US Cal Biomed Co LTD";s:7:"program";s:51:"Introduction of Shenyang International Biology Park";}i:20;a:3:{s:12:"time_program";s:7:"3:20 pm";s:19:"description_program";s:45:"John Shu, JD, Stradling Yocca Carlson & Rauth";s:7:"program";s:106:"The Foreign Corrupt Practices Act: Special Watchpoints for Bio/Pharmaceutical Companies Operating in China";}i:21;a:3:{s:12:"time_program";s:7:"3:40 pm";s:19:"description_program";s:101:"Peter Chen, PhD, President, Center for Innovation and Strategic Collaboration, St. Jude Medical, Inc.";s:7:"program";s:15:"Closing Remarks";}i:22;a:3:{s:12:"time_program";s:7:"3:50 pm";s:19:"description_program";s:0:"";s:7:"program";s:25:"Reception and Social Hour";}i:23;a:3:{s:12:"time_program";s:7:"8:00 am";s:19:"description_program";s:0:"";s:7:"program";s:34:"Registration Coffee and Breakfast";}i:24;a:3:{s:12:"time_program";s:7:"8:00 am";s:19:"description_program";s:0:"";s:7:"program";s:34:"Registration Coffee and Breakfast";}}
President, SABPA OC/LA
Matthew Jenusaitis, MBA.
President and CEO, OCTANe";s:7:"program";s:89:"Opening Remarks CA Medical Devices and the Importance of a Robust International Strategy";}i:2;a:3:{s:12:"time_program";s:9:"Session I";s:19:"description_program";s:51:"Moderator:Fred Ouyang, PhD, MBA.
Allergan, Inc";s:7:"program";s:52:"Global Trends in Biotech and Pharmaceutical Industry";}i:3;a:3:{s:12:"time_program";s:7:"8:45 am";s:19:"description_program";s:134:"Philip Schwartz, PhD.
Director, National Human Neural Stem Cell Resource, Childrens Hospital of Orange County Research Institute ";s:7:"program";s:54:"Human Neural Stem Cells for Therapy and Gene Discovery";}i:4;a:3:{s:12:"time_program";s:8:"9:15 am ";s:19:"description_program";s:59:"Ji Li, PhD.
Director, External R&D Affairs, Amgen Inc.";s:7:"program";s:28:"Partnering Approach at Amgen";}i:5;a:3:{s:12:"time_program";s:7:"9:45 am";s:19:"description_program";s:62:"William Martin, PhD.
Laboratory Director, PRL-SW, US FDA ";s:7:"program";s:168:"Adulteration in the Foods, Dietary Supplement/Herbal Products and Medical Products Industries: Domestic and Import Observations and the Quality Challenges to Industries";}i:6;a:3:{s:12:"time_program";s:8:"10:15 am";s:19:"description_program";s:0:"";s:7:"program";s:12:"Coffee Break";}i:7;a:3:{s:12:"time_program";s:10:"Session II";s:19:"description_program";s:59:"Moderator:Xiao-Yan Gong,PhD.
Medical Implant Mechanics";s:7:"program";s:37:"Innovation in Medical Device Industry";}i:8;a:3:{s:12:"time_program";s:8:"11:00 am";s:19:"description_program";s:87:"Sanjay Shrivastava, PhD.
Director, Research & Development, EV3 Neurovascular, Inc ";s:7:"program";s:104:"Materials and Design Considerations in Endovascular Treatments of Ischemic Stroke and Cerebral Aneurysms";}i:9;a:3:{s:12:"time_program";s:9:"11:30 am ";s:19:"description_program";s:90:"K. T. Rao, PhD.
Chief Scientific Officer and Vice President, Nellix Endovascular Inc.";s:7:"program";s:40:"Fillable Endovascular Aneurysm Treatment";}i:10;a:3:{s:12:"time_program";s:8:"12:00 pm";s:19:"description_program";s:0:"";s:7:"program";s:29:"Lunch and Visit Exhibit Booth";}i:11;a:3:{s:12:"time_program";s:11:"Session III";s:19:"description_program";s:43:"Moderator: Scott Lopez
Biotronik, Inc.";s:7:"program";s:27:"Global Operation Strategies";}i:12;a:3:{s:12:"time_program";s:7:"1:00 pm";s:19:"description_program";s:109:"Fidela Moreno MD, VP, Global Development Operations/ Clinical Site Management and Monitoring, Allergan Inc. ";s:7:"program";s:94:"The Globalization of Clinical Trials: Opportunities and Challenges for the Asia Pacific Region";}i:13;a:3:{s:12:"time_program";s:7:"1:20 pm";s:19:"description_program";s:50:"Sabing Lee, JD, Knobbe, Martens, Olson & Bear, LLP";s:7:"program";s:74:"Best Practices for Protecting Your Technology and IP in the U.S. and China";}i:14;a:3:{s:12:"time_program";s:7:"1:40 pm";s:19:"description_program";s:120:"Paul A. DeRidder, MD, MBA.
Venture Partner-Crystal Cove Capital, Partner-Ampleluck International Capital Group, Ltd";s:7:"program";s:39:"China Angel Investment: A New Beginning";}i:15;a:3:{s:12:"time_program";s:7:"2:00 pm";s:19:"description_program";s:120:"James Jiayuan Tong, MD, PhD.
Chief Financial Officer, Chief Business Development Officer Tianyin Pharmaceutical Co.";s:7:"program";s:55:"China BioMedical, PIPE's, M&A and other Exit Strategies";}i:16;a:3:{s:12:"time_program";s:7:"2:20 pm";s:19:"description_program";s:0:"";s:7:"program";s:5:"Break";}i:17;a:3:{s:12:"time_program";s:10:"Session IV";s:19:"description_program";s:58:"Moderator : John Shu, JD, Stradling Yocca Carlson & Rauth ";s:7:"program";s:29:"Global Economic Collaboration";}i:18;a:3:{s:12:"time_program";s:7:"2:40 pm";s:19:"description_program";s:66:"Andrew Pan, North America Representative Office of Shenzhen, China";s:7:"program";s:120:"Shenzhen-China's City of Innovation and Entrepreneurship--Update, Opportunities and Case Study in Biotechnology Industry";}i:19;a:3:{s:12:"time_program";s:7:"3:00 pm";s:19:"description_program";s:95:"Steve Jia, PhD, Co-founder and President , PacificBio Inc. & CTO, Shenyang US Cal Biomed Co LTD";s:7:"program";s:51:"Introduction of Shenyang International Biology Park";}i:20;a:3:{s:12:"time_program";s:7:"3:20 pm";s:19:"description_program";s:45:"John Shu, JD, Stradling Yocca Carlson & Rauth";s:7:"program";s:106:"The Foreign Corrupt Practices Act: Special Watchpoints for Bio/Pharmaceutical Companies Operating in China";}i:21;a:3:{s:12:"time_program";s:7:"3:40 pm";s:19:"description_program";s:101:"Peter Chen, PhD, President, Center for Innovation and Strategic Collaboration, St. Jude Medical, Inc.";s:7:"program";s:15:"Closing Remarks";}i:22;a:3:{s:12:"time_program";s:7:"3:50 pm";s:19:"description_program";s:0:"";s:7:"program";s:25:"Reception and Social Hour";}i:23;a:3:{s:12:"time_program";s:7:"8:00 am";s:19:"description_program";s:0:"";s:7:"program";s:34:"Registration Coffee and Breakfast";}i:24;a:3:{s:12:"time_program";s:7:"8:00 am";s:19:"description_program";s:0:"";s:7:"program";s:34:"Registration Coffee and Breakfast";}}
Registration (Lunch included):
$30 for pre-registration, $15 for students and post-docs, $40 for onsite registration
SABPA OCLA
